These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25323541)

  • 1. Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers.
    Sveikata A; Gumbrevičius G; Seštakauskas K; Kregždytė R; Janulionis V; Fokas V
    Medicina (Kaunas); 2014; 50(3):144-9. PubMed ID: 25323541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers.
    Lubenau H; Sveikata A; Gumbrevicius G; Macijauskiene J; Fokas V; Kazlauskas S; Janulionis V
    Int J Clin Pharmacol Ther; 2009 Apr; 47(4):275-82. PubMed ID: 19356394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.
    Lubenau H; Bias P; Maly AK; Siegler KE; Mehltretter K
    BioDrugs; 2009; 23(1):43-51. PubMed ID: 19344191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and Pharmacodynamic Equivalence of Pegfilgrastim-cbqv and Pegfilgrastim in Healthy Subjects.
    Finck B; Tang H; Civoli F; Hodge J; O'Kelly H; Vexler V
    Adv Ther; 2020 Oct; 37(10):4291-4307. PubMed ID: 32789809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial.
    Lickliter J; Kanceva R; Vincent E; Schueler A; Harrison-Moench E; Yue CS; Stahl M; Ullmann M; Ghori V; Griffin P
    Clin Ther; 2020 Aug; 42(8):1508-1518.e1. PubMed ID: 32660769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects.
    Singh I; Patel A; Patel R; Jose V
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):329-337. PubMed ID: 29948023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.
    Hu C; Ji B; Hu X; Yang C; Sun W; Zhao X; Li L; Li X; Zhang L
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):291-298. PubMed ID: 32567217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant filgrastim (BK0023) pharmacodynamics and pharmacokinetics after single and multiple escalating doses in an equivalence study in healthy men.
    Di Stefano AF; Spinetti G; Rusca A; Radicioni MM; Loprete L; Lamparelli DM; Michael Hepp J; Crobu D; Schrepfer R; Tonon G
    Clin Drug Investig; 2015 Sep; 35(9):533-45. PubMed ID: 26251016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: a randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers.
    Galán-Herrera JF; Poo JL; Maya-Barrios JA; de Lago A; Oliva I; González-de la Parra M; Jiménez P; López-Bojórquez E; Burke-Fraga V; Namur S
    Clin Ther; 2008 Sep; 30(9):1667-74. PubMed ID: 18840372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative pharmacokinetic and pharmacodynamic study of FSK0808 versus reference filgrastim after repeated subcutaneous administration in healthy Japanese men.
    Matsuguma K; Matsuki S; Sakamoto K; Shiramoto M; Nakagawa M; Kimura M; Irie S; Kaneko D; Ohnishi A
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):99-104. PubMed ID: 27128214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
    Waller CF; Tiessen RG; Lawrence TE; Shaw A; Liu MS; Sharma R; Baczkowski M; Kothekar MA; Micales CE; Barve A; Ranganna GM; Pennella EJ
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1087-1095. PubMed ID: 29671069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen
    Yao HM; Ottery FD; Borema T; Harris S; Levy J; May TB; Moosavi S; Zhang J; Summers M
    BioDrugs; 2019 Apr; 33(2):207-220. PubMed ID: 30900158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of FSK0808 and Gran after single intravenous drip administration or single subcutaneous administration: comparative study in healthy Japanese adult male subjects.
    Matsuguma K; Matsuki S; Eunhee C; Watanabe A; Tanaka A; Sakamoto K; Takeshita H; Hitaka A; Shigetome K; Kimura M; Miyamoto A; Irie S; Kaneko D; Ohnishi A
    Drug Dev Ind Pharm; 2015 Mar; 41(3):470-5. PubMed ID: 24471477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects.
    Singh I; Attrey A; Garg A; Patel R; Jose V
    Clin Drug Investig; 2021 Jan; 41(1):29-42. PubMed ID: 33236287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers.
    Wittayalertpanya S; Chariyavilaskul P; Prompila N; Sayankuldilok N; Eiamart W
    Int J Clin Pharmacol Ther; 2014 May; 52(5):431-6. PubMed ID: 24725445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers.
    Hernández-Bernal F; García-García I; González-Delgado CA; Valenzuela-Silva C; Soto-Hernández R; Ducongé J; Cervantes-Llano M; Blanco-Garcés E; Rodríguez V; García-Vega Y; Bello-Rivero I; Olivera-Ruano L; López-Saura P
    Biopharm Drug Dispos; 2005 May; 26(4):151-9. PubMed ID: 15799006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim.
    van Der Auwera P; Platzer E; Xu ZX; Schulz R; Feugeas O; Capdeville R; Edwards DJ
    Am J Hematol; 2001 Apr; 66(4):245-51. PubMed ID: 11279634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects.
    Nakov R; Gattu S; Wang J; Velinova M; Schaffar G; Skerjanec A
    Br J Clin Pharmacol; 2018 Dec; 84(12):2790-2801. PubMed ID: 30079636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg
    Roth K; Lehnick D; Wessels H; Höfler J; Gastl B; Jankowsky R
    Pharmacol Res Perspect; 2019 Oct; 7(5):e00503. PubMed ID: 31417680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of two intravenous formulations of antithrombin III: a two-way crossover study in healthy Korean subjects.
    Kim KA; Lim YY; Kim SH; Park JY
    Clin Ther; 2013 Nov; 35(11):1752-61. PubMed ID: 24094463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.